Abstract
Purpose To investigate whether wastewater treatment plant (WWTP) workers and residents living in close proximity to a WWTP have elevated carriage rates of ESBL-producing Enterobacterales, as compared to the general population.
Methods From 2018 to 2020, we carried out a cross-sectional study in Germany, the Netherlands, and Romania among WWTP workers (N=344), nearby residents (living ≤ 300 meters away from WWTPs; N=431) and distant residents (living ≥ 1000 meters away = reference group; N=1165). We collected information on potential confounders via questionnaire. Culture of participants’ stool samples was performed with ChromID®-ESBL agar plates and species identification with MALDI-TOF-MS. We used logistic regression to estimate the odds ratio (OR) for carrying ESBL-producing E. coli (ESBL-EC). Sensitivity analyses included stratification by country and interaction models using country as secondary exposure.
Results Prevalence of ESBL-EC was 11% (workers), 29% (nearby residents), and 7% (distant residents), and higher in Romania (28%) than in Germany (7%) and the Netherlands (6%). Models stratified by country showed that within the Romanian population, WWTP workers are about twice as likely (aOR = 2.34, 95% CI: 1.22-4.5) and nearby residents about three times as likely (aOR = 3.17, 95% CI: 1.8-5.59) to be ESBL-EC carriers, when compared with distant residents.
Conclusions In stratified analyses by country, we found an increased risk for carriage of ESBL-EC in Romanian workers and nearby residents. This effect was higher for nearby residents than for workers, which suggests that, for nearby residents, factors other than the local WWTP could contribute to the increased carriage.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.mdpi.com/2079-6382/10/5/478
Funding Statement
AWARE (Antibiotic Resistance in Wastewater: Transmission Risks for Employees and Residents around Wastewater Treatment Plants) is supported by the European Commission (JPI-EC-AMR ERA- Net Cofund grant no 681055), the Bundesministerum für Bildung und Forschung, DLR Projektträger (01KI1708), UEFISCDI project ERANET-JPI-EC-AMR-AWARE-WWTP No. 26/2017, the Netherlands Organisation for Health Research and Development, The Hague, the Netherlands (ZonMw, grant 547001007, https://www.zonmw.nl/), and the Swedish Research Council VR Grant No. 2016-06512, all within the 5th JPI AMR framework on transmission dynamics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval This study was approved by the Ethics Committee of the University of Munich (LMU) (Project-No. 17- 734) and by the Research Ethics Committee of the University of Bucharest (Registration-No. 164/05.12.2017). In the Netherlands, this research is exempted for ethical approval under the Dutch Medical Research Involving Human Subjects Act (WMO; Committee: Medisch Ethische Toetsingscommissie, number of confirmation: 19-001/C). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards, as well as with Directive 95/46/EC, and the 1977 Oviedo Convention of the Council of Europe on human rights and biomedicine. Consent to participate Written informed consent was obtained from all individual participants included in the study and their legal guardians when applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and materials are available upon request.
